Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UNIPROT:P01185 (vasopressin)
 23,126 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

This review summarizes the results obtained with ibopamine on anaesthesized dogs. Ibopamine is a dopamine-related drug active by oral route, namely the diisobutyric ester of N-methyl-dopamine. Ibopamine is able to activate dopamine specific and adrenergic receptors in the heart and circulation, inducing a vasodilating activity together with a mild positive inotropic effect without increasing heart rate and myocardial O2 consumption. The activation of dopamine and adrenergic receptors mediates a direct vasodilation postjunctional DA1 and beta 2 receptors and an indirect vasodilation (presynaptic DA2 and alpha 2-receptors) through the inhibition of the release in norepinephrine, the renin-angiotensin system, and the secretion of aldosterone and vasopressin, thus antagonizing the neurohormonal alterations in congestive heart failure through a receptor mechanism. Ibopamine can also activate beta 1- and beta 2 and very modestly vascular synaptic alpha 1- and alpha 2-receptors, thus inducing a mild positive inotropic activity and avoiding a drop in arterial pressure which might take place in presence of the intense vasodilation induced by the drug. There is some difference in potency between dopamine and epinine. Epinine is the active metabolite of ibopamine and is more active than dopamine on DA1, DA2, alpha 1, alpha 2 and beta 1 and beta 2 receptors. Ibopamine can be safely associated with captopril and digoxin but not with nifedipine.
 ...
PMID:Pharmacological profile of ibopamine. A summary of experiments on anaesthesized dogs. 198 Jun 31

Diuretic effect of orally administered ibopamine (SB-7505), the 3,4-diisobutyryl ester of N-methyldopamine, was studied in normally hydrated and in experimentally oliguric rats. In normal rats ibopamine proved to be active in increasing urine volume as well as sodium and chlorine excretion. The diuretic effect set in rapidly and reached the maximum in the first 2 h after treatment; repeated daily treatment constantly increased urine and ions excretion. Ibopamine proved to be more active in oliguric than in normal rats; when administered orally in combination with furosemide it maintained its diuretic effect, which was additional to that of furosemide. Possible ibopamine interaction with antidiuretic hormone and sodium reabsorption as well as its use also in combination with diuretic agents in renal failure are discussed.
 ...
PMID:Effect of ibopamine on diuresis in conscious rats in normal and experimentally altered conditions. 370 42

A survey is given of the currently used therapeutics in the treatment of chronic congestive heart failure. Symptomatic treatment is usually performed along the following lines: rest, sodium and fluid restriction to unload the decompensating heart, loop diuretics, angiotensin-converting enzyme inhibitors or other vasodilators; inotropic agents to improve the heart's mechanical performance; attempts to counteract the neuro-endocrine compensatory mechanisms, that is the activated sympathetic nervous and renin-angiotensin-aldosterone systems, as well as the rise in vasopressine levels. New insights have been obtained in the effects of cardiac glycosides, which are probably rather based on counteracting the elevated sympathetic neuronal activity than on their weak and uncertain inotropic action. Angiotensin-converting enzyme inhibitors are probably more effective than classical vasodilators owing to their additional interaction with the neuro-endocrine compensatory mechanisms. Ibopamine, a prodrug of epinine, appears to be rather a vasodilator and antagonist of the neuro-endocrine compensatory mechanisms than an inotropic agent. The most important clinical trials addressing the efficacy and adverse reactions to the various aforementioned therapeutics are discussed. New, experimental approaches in the drug treatment of chronic congestive heart failure include beta-blockers, calcium antagonists, vasopressin antagonists and inhibitors of atrial natriuretic peptide degradation.
 ...
PMID:Pharmacotherapy of congestive heart failure. Currently used and experimental drugs. 788 21